




Article

Modeling the Effects of Cypermethrin Toxicity on Ovalbumin-Induced Allergic Pneumonitis Rats: Macrophage Phenotype Differentiation and p38/STAT6 Signaling Are Candidate Targets of Pirfenidone Treatment

Ahmed A. Morsi ^{1,*}, Eman Mohamed Faruk ^{2,3}, Mysara Mohamed Mogahed ⁴, Bodour Baioumy ⁵, Asmaa Y. A. Hussein ⁶, Rabab Shaban El-shafey ⁶, Ezat A. Mersal ^{7,8}, Ahmed M. Abdelmoneim ⁹, Mohammed M. Alanazi ¹⁰ and Amal Mahmoud ElSafy Elshazly ⁵

¹ Department of Histology and Cell Biology, Faculty of Medicine, Fayoum University, Fayoum 63511, Egypt

² Anatomy Department, College of Medicine, Umm Al-Qura University, Makkah 24382, Saudi Arabia; emkandel@uqu.edu.sa

³ Department of Histology and Cytology, Faculty of Medicine, Benha University, Benha 13511, Egypt

⁴ Department of Internal Medicine, Faculty of Medicine, Benha University, Benha 13511, Egypt

⁵ Department of Anatomy and Embryology, Faculty of Medicine, Benha University, Benha 13511, Egypt

⁶ Forensic Medicine and Clinical Toxicology Department, Faculty of Medicine, Benha University, Benha 13511, Egypt

⁷ Biochemistry Department, Faculty of Science, Assiut University, Assiut 71515, Egypt

⁸ Department of Basic Medical Sciences, Vision Colleges, Riyadh 11451, Saudi Arabia

⁹ Physiology Department, Faculty of Medicine, Fayoum University, Fayoum 63511, Egypt

¹⁰ Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia

* Correspondence: aaa21@fayoum.edu.eg



Citation: Morsi, A.A.; Faruk, E.M.; Mogahed, M.M.; Baioumy, B.; Hussein, A.Y.A.; El-shafey, R.S.; Mersal, E.A.; Abdelmoneim, A.M.; Alanazi, M.M.; Elshazly, A.M.E. Modeling the Effects of Cypermethrin Toxicity on Ovalbumin-Induced Allergic Pneumonitis Rats: Macrophage Phenotype Differentiation and p38/STAT6 Signaling Are Candidate Targets of Pirfenidone Treatment. *Cells* **2023**, *12*, 994. <https://doi.org/10.3390/cells12070994>

Academic Editors: Mingyao Liu and Yasu-Taka Azuma

Received: 4 January 2023

Revised: 10 March 2023

Accepted: 20 March 2023

Published: 24 March 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: Although the classic form of asthma is characterized by chronic pneumonitis with eosinophil infiltration and steroid responsiveness, asthma has multifactorial pathogenesis and various clinical phenotypes. Previous studies strongly suggested that chemical exposure could influence the severity and course of asthma and reduce its steroid responsiveness. Cypermethrin (CYP), a common pesticide used in agriculture, was investigated for the possible aggravation of the ovalbumin (OVA)-induced allergic pneumonitis and the possible induction of steroid resistance in rats. Additionally, it was investigated whether pirfenidone (PFD) could substitute dexamethasone, as an alternative treatment option, for the induced steroid resistance. Fifty-six male Wistar albino rats were randomly divided into seven groups: control, PFD alone, allergic pneumonitis, CYP alone, allergic pneumonitis/CYP-exposed, allergic pneumonitis/CYP/dexamethasone (Dex), and allergic pneumonitis/CYP/PFD-treated groups. Allergic pneumonitis was induced by three intraperitoneal OVA injections administered once a week, followed by an intranasal OVA instillation challenge. CYP (25 mg/kg/d), Dex (1 mg/kg/d), and PFD (100 mg/kg/d) were administered orally from day 15 to the end of the experiment. Bronchoalveolar lavage fluid (BALF) was analyzed for cytokine levels. Hematoxylin and eosin (H&E) and periodic acid Schiff (PAS)-stained lung sections were prepared. Immunohistochemical identification of p38 MAPK and lung macrophages was performed. The inflammatory/oxidative status of the lung and PCR-quantification of the STAT6, p38 MAPK, MUC5AC, and IL-13 genes were carried out. The allergic pneumonitis-only group showed eosinophil-mediated inflammation ($p < 0.05$). Further CYP exposure aggravated lung inflammation and showed steroid-resistant changes, p38 activation, neutrophil-mediated, M1 macrophage-related inflammation ($p < 0.05$). All changes were reversed ($p < 0.05$) by PFD, meanwhile not by dexamethasone treatment. Pirfenidone could replace dexamethasone treatment in the current rat model of CYP-induced severe steroid-resistant asthma via inhibiting the M1 macrophage differentiation through modulation of the STAT6/p38 MAPK pathway.

Keywords: asthma exacerbation; CD86/CD206 immunohistochemistry; environmental triggers; p38/STAT6; Th2/Th1 inflammation

1. Introduction

Asthma is a chronic disabling respiratory disorder associated with a negative impact on the affected individuals' socioeconomic status and quality of life. The global number of asthmatic individuals was reported to be increasing, reaching 300 million cases, including all age groups. The annual death rate due to asthma was reported to be about 250 thousand cases/year [1].

Microstructural and functional changes in the asthmatic patients' lungs are cardinal signs attributed to T helper2 (Th2)-mediated inflammatory response due to Th1/Th2 imbalance [2]. Two clinical asthma variants (Th2 high and Th2 low) are known based on the clinical presentation and biochemical assays. Th2-high asthma is the classic allergic asthma manifested by high Th2-related cytokine (IL4, 5, and 13), eosinophils recruitment, goblet cell proliferation, and mucous hypersecretion. The Th2-low variant is usually a severe form, triggered by environmental pollutants, and manifested by high Th1/Th17-related cytokine levels, neutrophil recruitment, and steroid resistance [3].

The development of asthma is controlled by different regulators and transcription factors whose targeted therapy could be a viable option for treatment. The signal transducer and activator of transcription (STAT) family and mitogen-activated protein kinase (MAPK) are common molecular pathways in allergic asthma [4]. STAT6 activation mediates the classic Th2-high asthma response [5], whereas p38 MAPK activation is usually related to severe Th2-low asthma [6].

Exposure to environmental triggers, such as insecticides in agriculture, can initiate an asthmatic response in susceptible individuals, called occupational asthma [7]. Cypermethrin (CYP) is a highly active, commonly used synthetic pyrethroid pesticide. They are prevalent in agriculture, replacing prohibited insecticides such as organophosphate. Being a lipophilic compound, it could affect biological membranes with cardiovascular, nervous, immune, and genetic toxicity [8]. Exposure may be occupational, household, or accidental based on an adventure background. CYP was proven to have a toxic effect on aquatic species, mammals, and birds [9].

Pirfenidone (PFD) is a synthetic pyridine derivative approved in many countries as a recommended agent in treating idiopathic pulmonary fibrosis (IPF). Anti-inflammatory and anti-fibrotic actions were suggested mechanisms through inhibiting cytokine release, such as TNF-alpha and IL-6, suppression of inflammatory cell infiltration, and enhancement of inflammasomes [10]. The lack of literature studies emphasizing the curative leverage potential of PFD against environmental pollutants-induced severe asthma caught the authors' attention for investigating pirfenidone versus dexamethasone.

Chronic asthma patients are susceptible individuals whose allergy could be worsened by insecticide exposure due to immunological shifts and alterations [11]. Therefore, the aim of the study was, first, to investigate the possible exacerbation of severe allergic lung inflammation and the possible induction of steroid resistance, due to oral CYP exposure, in concurrently existing asthma in albino rats. The current experiment is unique, investigating asthmatic immunoreactivity in a combined OVA-sensitization/CYP exposure model in rats. Second, the authors hypothesized that pirfenidone might be a proper alternative, versus dexamethasone, in treating the possible induced steroid resistance due to CYP exposure, using histological and biochemical approaches.

2. Materials and Methods

2.1. Chemicals and Drugs

Ovalbumin, OVA ($\geq 97\%$ purity powder, catalog #: S7951), and carboxymethyl cellulose (CMC 1%, catalog #: 419273) were purchased from Sigma-Aldrich, St. Louis, MO, USA.

Aluminum hydroxide ($\text{Al}(\text{OH})_3$) was purchased from ThermoFisher Scientific (Waltham, MA, USA) (catalog #: AC219130250). Cypermethrin (20% emulsion concentration) was purchased from Kafr El Zayat Company for pesticides and chemicals, Gharbia, Egypt. Pirfenidone (Pirfenex 200 mg tab) was manufactured by Cipla LTD., Taza Block, Sikkim, India. Dexamethasone (Deltason 0.75 mg tab) was manufactured by Nile Company (Cairo, Egypt) for pharmaceutical industries in Egypt.

2.2. Preparation and Dosage of Pirfenidone, Dexamethasone, Ovalbumin, and Cypermethrin

Both pirfenidone (PFD) and dexamethasone (Dex) tablets were ground and suspended in 1% carboxymethyl cellulose. One pirfenidone tablet was dissolved in 4 mL CMC to obtain a final concentration of 50 mg/mL and was given in a dose of 100 mg/kg/d oral gavage for two weeks [10]. Two dexamethasone tablets were dissolved in 3 mL CMC to obtain a final concentration of 0.5 mg/mL and were given in a dose of 1 mg/kg/day orally for two weeks [12]. Ovalbumin (OVA) solution was prepared (emulsified in aluminum hydroxide (adjuvant)) as previously described by Tang et al. [13] Both OVA (200 $\mu\text{g}/\text{mL}$) and aluminum hydroxide (40 mg/mL) were dissolved in normal saline, each per 1 mL saline; so, 1 mL solution contained 100 μg OVA and 20 mg $\text{Al}(\text{OH})_3$. Cypermethrin (CYP) was dissolved in corn oil and administered via oral gavage, 25 mg/kg/d (1/10 of $\text{LD}_{50}\%$), in a total volume of 5 mL/kg/d [14].

2.3. Induction of Allergic Asthma

For sensitization and challenge of rats, the method of Tang et al. [13] was followed with minor modifications. Each rat received 100 μL of the prepared OVA solution, intraperitoneal (i.p.), on days 0, 7, and 14. One week later, on the 21st day and to the 28th day, the rats were challenged daily by intranasal OVA instillation (Figure 1). For the challenge, the animals were lightly anesthetized and received OVA solution, 40 mg/mL; 20 $\mu\text{L}/\text{rat}$ in nostrils to the nasal cavity.




Figure 1. Diagrammatic representation of the different timepoints of the current experiment. i.p.: intraperitoneal, i.n.: intranasal, OVA: ovalbumin, CYP: cypermethrin, PFD: pirfenidone, Dex: dexamethasone.

2.4. Animals

Wistar male albino rats ($n = 56$, 6-week-old, 170–190 g bodyweight) were purchased from the breeding unit of the experimental animals' farm, Helwan, Cairo, Egypt. For adaptation, the animals were fed for one week in the Anatomy Lab, Faculty of Medicine, Benha University, Egypt, before the experiment. The animals were housed in suitable living conditions (ambient temperature of $23 \pm 2^\circ\text{C}$, 55% humidity, and 12 h light/dark cycle) and food/water were allowed ad libitum. The study protocol was approved by the Research Ethics Committee at the Faculty of Medicine, Benha University, Egypt (approval #: RC11-10-2022).

2.5. Study Groups

The animals were randomly divided into seven groups, eight rats each: The control, Pirfenidone (PFD) alone, allergic pneumonitis-only, cypermethrin (CYP) alone, allergic/CYP, allergic/CYP/Dex, and allergic/CYP/PFD groups. In the control group, the rats received normal saline containing Al(OH)₃ only by i.p. injection and were challenged by intranasal saline instillation, oral CMC 1%, and corn oil. The vehicles were given in the same volume and at the same time point, similar to the experimental groups. Dexamethasone was used herein as a reference drug for comparison with pirfenidone. CYP, PFD, and Dex were given orally and simultaneously from day 15 to day 28 (Figure 1). CYP was given at 9 am, PFD at 3 pm, and Dex at 9 pm to avoid possible drug–drug interaction.

2.6. Blood Sampling

Twenty-four hours after the last treatment, terminal blood samples were obtained from the heart of the anesthetized animals, centrifuged (176× g for 10 min), and supernatant sera were collected and stored at −20 °C for later analysis of serum IgE.

2.7. Bronchoalveolar Lavage Fluid (BALF) Preparation

After blood sampling, the anesthetized rats were sacrificed by cervical dislocation. Three animals per group were used for BALF collection. The trachea was cannulated after opening the chest and dissecting thoracic organs. Both lungs were washed with 5 mL of normal saline through the cannulated trachea with a light massage. Washing was repeated twice; then, the BALF was withdrawn (volume recovery rate more than 75%) and centrifuged (12× g for 10 min). For cell counting, the pellets were resuspended in 200 µL PBS and cells were manually counted by a hemocytometer under light microscopy after Giemsa staining. At least 200 cells were counted at high magnification (×400) [15]. Additionally, TNF-α, IL13, INF-γ, and IL-17 were measured in the BALF's supernatants using rat-specific ELISA kits, following the manufacturer's guidelines. The sensitivity of the assayed cytokines was 9.38 pg/mL for TNF-α and IL13, 7 pg/mL for INF-γ, and 3.9 pg/mL for IL17.

2.8. Lung Tissue Sampling

In each animal group, both lungs were resected, rinsed in cooled saline to remove blood clots, and separated into left and right lungs. The left lungs were stored at −20 °C for later molecular study and biochemical analysis of tissue homogenates. The right lungs were fixed in formal saline for histological and immunohistochemical study. Lung lavage was not performed in animals whose lung samples were used for histology and immunohistochemistry.

2.9. Tissue Homogenate Analysis of TNF-α, MDA, SOD

The collected lung samples were homogenized and centrifuged at 4 °C (704× g, for 20 min). The obtained supernatants were frozen at −20 °C for later measurement of tumor necrosis factor-α (TNF-α), malondialdehyde (MDA), and superoxide dismutase (SOD) using ELISA assay. Rat-specific kits for MDA and SOD were purchased from MyBioSource, San Diego, CA, USA, catalog #: MBS738685 and MBS036924, respectively. For TNF-α, the kits were purchased from Elabscience, Houston, TX, USA, catalog #: E-EL-R2856.

2.10. PCR Assay for Quantification of STAT6, p38MAPK, MUC5AC, and IL-13 Gene Expressions

Initial homogenization of the collected lung samples was carried out. The total RNA was isolated using RNeasy Mini Kit (Cat No./ID: 74104, Qiagen, Germantown, MD, USA) and spectrophotometric (JENWAY, Long Branch, NJ, USA) determination of the RNA concentration was carried out at 260 nm. The mRNA was converted into cDNA using a PCR Master Mix kit (catalog #: 4440040, Applied Biosystems, Waltham, MA, USA). The PCR amplification/analysis was evaluated by StepOneSystem (RQ Manager 1.2, software v 2.1, Applied Biosystem, USA). The result of the targeted genes (STAT6, p38, MUC5AC, and IL-13)

was normalized to an endogenous housekeeping gene GAPDH. The comparative $2^{-\Delta\Delta Ct}$ method was used for the calculation of the relative fold gene expression, as demonstrated by Livak & Schmittgen [16]. For polymerase activation/reverse transcriptase inactivation, the thermocycler was set at 45 °C, followed by 95 °C (for 15 and 5 min, respectively) [17]. For detection of the rat *STAT6*, *p38*, *MUC5AC*, and *IL-13* transcripts, the primer sequences (Table 1) were taken from NCBI GenBank at the following website: <http://www.ncbi.nlm.nih.gov/tools/primer-blast> (accessed on 1 January 2023). A melting temperature of 60–65 °C and a length of approximately 90–200 bp were considered when selecting the ideal primer pair.

Table 1. PCR primers sequences and accession numbers of the studied genes.

Gene	Accession Number	Primer Sequence (5' → 3')
Signal transducer and activator of transcription 6 (<i>STAT6</i>)	NM_001044250.1	F: GAGCTACTGGTCAGATCGGC R: GGTCCATCTGGCTCGTTGA
Mitogen-activated protein kinase p38 (<i>p38 MAPK</i>)	NM_031020.3	F: TCGGCACACTGATGACGAAA R: TCATGGCTTGGCATCCTGTT
Mucin 5AC (<i>MUC5AC</i>)	XM_039101269.1	F: GTTTCCTGCACCATGTCAGGC R: TGGGGCGGTAGATGTGGATA
Interleukin 13 (<i>IL-13</i>)	NM_053828.1	F: TCTCGCTTGCCTTGGTGG R: CATTCAATATCCTCTGGGCTCTGT
Glyceraldehyde 3- phosphate dehydrogenase (<i>GAPDH</i>)	NM_001394060.2	F: GGTGCTGAGTATGTCGTGGAG R: ACAGTCTTCTGAGTGGCAGTGAT

F: forward, R: Reverse.

2.11. Histological Procedure

The right lung of each rat per group was processed for paraffin section preparation after 48- hour-fixation in 10% formol saline at room temperature. The samples were dehydrated by passing through ascending grades of ethanol (70%, 90%, and 100%), cleared in xylene, infiltrated, and embedded in paraffin. For each paraffin block, five-micrometer cut sections were prepared for histological stains. Sections were deparaffinized, rehydrated in descending grades of ethanol, and manually stained with hematoxylin and eosin (H&E) and periodic acid Schiff (PAS) [18].

2.12. Immunohistochemical Identification of CD86, CD206, and p38 MAPK

The formalin-fixed, paraffin-processed cut sections of the lungs were mounted on positively charged glass slides. They were subjected to the sequential steps of the immunohistochemical assay [19] to identify p38 MAPK and CD markers of macrophage phenotypes (CD86, CD206). The primary antibodies (CD86, p38, and CD206) were all rabbit polyclonal antibodies purchased from ABclonal Inc., Woburn, MA, USA (catalog #: A2353, A14401, respectively). CD206 was purchased from ThermoFisher Scientific (catalog #: PA5-101657). After deparaffinization and rehydration, the sections were boiled in citrate buffer (Thermo Fisher Scientific, Eprelia, catalog #: AP9003-125) for 10 min at pH 6 to retrieve the antigen, and were then cooled naturally. The slides were incubated with an H₂O₂ solution (15 min) to block endogenous peroxidase activity. Block the sections with the corresponding protein. Then, the lung sections were incubated with the primary antibodies overnight at 4 °C (at dilutions 1:200 for p38 and CD86, 1:100 for CD206). Each step mentioned was followed by PBS washing. For completing the immunoreaction, a rabbit-specific anti-polyvalent HRP/DAB ultravision detection system was used (TP-015-HD, Lab Vision™, Thermo Fisher Scientific). The 3,3-diaminobenzidine (DAB) chromogen and hematoxylin counterstaining were used.

The CD86 and CD206 immunopositivity was marked by brownish cytoplasmic coloration. For p38, positive nuclear and cytoplasmic reaction was identified. The positive controls were mouse spleen, mouse lung, and human heart for CD86, CD206, and p38, respectively. The negative control slides were arranged by skipping the step of the primary antibody. The slides were examined and photographed by a Nikon Eclipse 80i microscope (Nikon Corporation, Tokyo, Japan) provided with TouPCam™ Xcam full HD camera

(ToupTek Europe, Ultramicro Ltd., Suffolk, UK). Slide examination and photography were done in the Department of Anatomy and Embryology, Faculty of Medicine, Benha University, Egypt.

2.13. Morphometric Study

Blind image analysis was conducted by an expert in the field from whom the study groups' information was withheld. This was performed using ImageJ software (Java; NIH, Bethesda, MD, USA), which was calibrated to analyze the captured photomicrographs [20]. The PAS-stained slides were used for calculating the goblet cell number (GCN); meanwhile, the H&E-staining was used for measurement of the eosinophil number (EN), neutrophil number (NN), perivascular inflammation, peribronchiolar inflammation, and alveolar wall thickness. For GCN measurement, the goblet cells were counted per five round cross-cut bronchioles in each section per group at $\times 200$ magnification. The average goblet cells/bronchiole was obtained by dividing the total number by five, according to Tang et al. [21] with minor modifications. For eosinophil and neutrophil numbers, the peribronchial cells were counted in five bronchioles in each section, and the parenchymal cells were counted in five fields at $\times 200$. The average EN or NN/field was calculated by dividing the obtained number by five [22]. The perivascular and peribronchiolar inflammation was assessed by counting the number of complete layers of mononuclear cells (MNCs) around blood vessels and bronchioles, respectively, as follows: 0 (absence or presence of few MNCs), 0.1–0.9 (incomplete layer), 1 (one complete layer), 2 (two complete layers), 3 (three complete layers), 4 (more than three complete layers) according to Wu et al. [23]. The immunoassay-based slides were used for measurement of the area percentage of p38 MAPK immunopositivity and counting the number of the CD86- and CD206-positive macrophages. The macrophage phenotype was counted for those located peribronchial and interstitially in 5 bronchioles/or fields.

2.14. Statistical Analysis

The normality check and even distribution of variables were initially carried out by applying Shapiro's test. One-way analysis of variance (ANOVA) was used to detect the statistical significance, accompanied by post hoc Tukey's test for multiple groups comparison. The measurements of CD86 and CD206 positive macrophages were carried out by two-way ANOVA followed by Tukey's test for comparison between the groups and the two variables within each group. All data were expressed as mean \pm SD. The data analyses were conducted using GraphPad Prism software, v8.0, for windows (GraphPad Software Inc., San Diego, CA, USA). Statistical significance was considered at $p < 0.05$. G*power software version 3.0.10 was used to determine the total sample size and the number of rats per group [24]. The initial setting of the software was carried out, and an a priori type of power analysis was selected, power 80, alpha level 5%, and a desired effect size 0.55, predetermined based on the parallel finding of similar studies and experience in the field area. Thus, eight rats per group were statistically adequate.

3. Results

3.1. Pirfenidone Reversed the Serum Level of IgE

The serum immunoglobulin E (IgE) level showed a remarkable elevation ($p < 0.05$) in the allergic pneumonitis group, compared to the control IgE levels. CYP exposure of the allergic pneumonitis (allergic pneumonitis/CYP) group caused a significant decrease in the IgE level ($p < 0.05$), compared to the allergic pneumonitis-only group. Pirfenidone treatment (allergic/CYP/PFD group) versus dexamethasone (allergic/CYP/Dex group) showed a marked decrease ($p < 0.05$) in the IgE level when compared to the allergic/CYP group. No significant difference was noticed between the control and PFD-alone treatment (Table 2).

Table 2. The effect of pirfenidone on the serum IgE and BALF levels of inflammatory cytokines, eosinophil, and neutrophil count in allergic pneumonitis/CYP-exposed rats at the end of the experiment.

	Serum IgE (ng/mL)	BALF TNF- α (pg/mL)	BALF IL13 (pg/mL)	BALF IL17 (pg/mL)	BALF INF- γ (pg/mL)	BALF Neutrophil Count/mm ³	BALF Eosinophil Count/mm ³
Control	12.7 \pm 2.02	22.02 \pm 2.2	37.1 \pm 2.4	53.6 \pm 4.9	8.7 \pm 1.1	0.25 \pm 0.5	0.38 \pm 0.7
Pirfenidone (PFD)	13.1 \pm 2.2	23.04 \pm 2.9	37.3 \pm 2.9	51 \pm 3.7	9 \pm 1.1	0.13 \pm 0.4	0.63 \pm 0.7
Allergic pneumonitis	95 \pm 6.1 a ($p < 0.01$)	83 \pm 8.4 a ($p < 0.01$)	184.5 \pm 9 a ($p < 0.01$)	90.2 \pm 3.1 a ($p < 0.01$)	11.8 \pm 1.5 a ($p = 0.01$)	0.75 \pm 0.7	120.9 \pm 6.2 a ($p < 0.01$)
CYP	12.3 \pm 2.3	58.9 \pm 6.1 a ($p < 0.01$)	44.7 \pm 3.6	57.5 \pm 5.6	12.4 \pm 1.5 a ($p = 0.01$)	1 \pm 0.8	1.9 \pm 1.8
Allergic/CYP	83.7 \pm 7.3 ab ($p < 0.01$)	69.8 \pm 9.4 ab ($p < 0.01, = 0.003$)	132.4 \pm 6.9 ab ($p < 0.01$)	172.4 \pm 16 ab ($p < 0.01$)	18.9 \pm 1.5 ab ($p < 0.01$)	18.6 \pm 4.3 ab ($p < 0.01$)	15.5 \pm 3.5 ab ($p < 0.01$)
Allergic/CYP/Dex	77.9 \pm 3.2	69.9 \pm 8.3	123.9 \pm 5.9	174 \pm 12.8	19.7 \pm 2	16.6 \pm 5.2	11.5 \pm 2.3
Allergic/CYP/PFD	18.6 \pm 3.3 bc ($p < 0.01$)	21.5 \pm 3.7 bc ($p < 0.01$)	36.2 \pm 4.9 bc ($p < 0.01$)	50.9 \pm 4 bc ($p < 0.01$)	9.9 \pm 2.1 bc ($p = 0.03, < 0.01$)	2.6 \pm 1.6 c ($p < 0.01$)	1 \pm 0.8 bc ($p < 0.01$)

The data are presented as a mean \pm SD ($n = 8$ serum and 3 BALF samples). Superscript letters indicate the significant difference and the p -value between groups. ^a: versus control, ^b: versus allergic group, ^c: versus allergic/CYP and allergic/CYP/Dex groups, using post hoc Tukey's one-way ANOVA test.

3.2. Pirfenidone Suppressed Inflammatory Cytokines, Eosinophilic and Neutrophilic Count in BALF

The inflammatory status was assessed by measuring TNF- α , INF- γ , IL13, IL17, and cell counts in bronchoalveolar lavage fluid (BALF) (Table 2). The four measured cytokines and eosinophil count showed a remarkable elevation ($p < 0.05$) in the allergic pneumonitis group when compared to the corresponding control levels. CYP-alone exposure led to a significant elevation ($p < 0.05$) in TNF- α and INF- γ levels compared to the control group. CYP exposure of the allergic pneumonitis (allergic/CYP) group shifted the cell count toward neutrophil ($p < 0.05$) and caused a further significant increase ($p < 0.05$) in the BALF levels of INF- γ and IL17 only when compared to the allergic pneumonitis-only group. Pirfenidone (allergic/CYP/PFD group) versus dexamethasone treatment (allergic/CYP/Dex group) showed a marked decrease ($p < 0.05$) in all measurements when compared to the allergic/CYP group. No significant difference was noticed between the control and PFD-alone treatment.

3.3. Pirfenidone Alleviated Inflammation and Oxidative Stress in the Lung Tissues

MDA, SOD, and TNF- α were measured in the lung tissue homogenates to evaluate inflammation and the oxidant/antioxidant condition (Table 3). Both MDA and TNF- α levels showed a remarkable elevation ($p < 0.05$) in the allergic pneumonitis and CYP alone groups when compared to the control group. CYP exposure of the allergic pneumonitis (allergic/CYP) group caused a further significant increase ($p < 0.05$) in the MDA and TNF- α measurements when compared to the allergic pneumonitis-only group. Inversely, the SOD level was markedly decreased ($p < 0.05$) in the allergic pneumonitis group, and a lower level ($p < 0.05$) was observed in the allergic/CYP group. Pirfenidone treatment (allergic/CYP/PFD) group versus dexamethasone significantly ameliorated ($p < 0.05$) the oxidative changes. No significant difference was noticed between the control and PFD-alone treatment.

Table 3. The effect of pirfenidone on the lung tissue concentrations of MDA, SOD, and TNF- α in CYP-exposed allergic pneumonitis rats at the end of the experiment.

	MDA ($\mu\text{mol/mL}$)	SOD (mmol/min/mg)	TNF- α ($\text{pg}/100 \mu\text{g Protein}$)
Control	17.2 \pm 2	96.9 \pm 9.4	11.9 \pm 2.7
Pirfenidone (PFD)	17.4 \pm 2.1	98.1 \pm 7	12.9 \pm 1.8
Allergic	34.7 \pm 4.7 ^a ($p < 0.01$)	25.6 \pm 3.4 ^a ($p < 0.01$)	19.3 \pm 2.5 ^a ($p = 0.01$)
CYP	42.1 \pm 3.8 ^a ($p < 0.01$)	34.8 \pm 9.1 ^a ($p < 0.01$)	32.2 \pm 2.3 ^a ($p < 0.01$)
Allergic/CYP	77.07 \pm 4.2 ^{ab} ($p < 0.01$)	12.8 \pm 2.4 ^{ab} ($p < 0.01, = 0.03$)	42.6 \pm 3.6 ^{ab} ($p < 0.01$)
Allergic/CYP/Dex	81.6 \pm 8.3	14.8 \pm 3.4	43.4 \pm 1.1
Allergic/CYP/PFD	22.7 \pm 5.4 ^{bc} ($p < 0.01$)	73 \pm 7.7 ^{abc} ($p < 0.01$)	12.6 \pm 2.8 ^{bc} ($p = 0.004, < 0.01$)

The data are presented as a mean \pm SD ($n = 5$ lung tissue samples). Superscript letters indicate the significant difference and the p -value between groups. ^a versus control, ^b versus allergic group, ^c versus allergic/CYP, and allergic/CYP/Dex groups, using post hoc Tukey's one-way ANOVA test.

3.4. Pirfenidone Modulated STAT6, p38MAPK, MUC5AC, and IL-13 Gene Expression

The PCR assay of lung samples was displayed in Figure 2. The *IL-13*, *MUC5AC*, *STAT6*, and *p38* mRNA expression showed a significant rise ($p < 0.001$) in the allergic pneumonitis group when compared to the control gene values. Furthermore, CYP exposure in the allergic pneumonitis rats resulted in more increase ($p < 0.003$) in *MUC5AC* and *p38* gene expression (Figure 2b,c, respectively); meanwhile, the *IL-13* and *STAT6* (Figure 2a,d, respectively) showed a further decrease ($p < 0.05$), in comparison to the allergic pneumonitis-only group. Pirfenidone treatment (allergic/CYP/PFD group) versus dexamethasone (allergic/CYP/Dex) group showed a significant reversal ($p < 0.05$) of the altered gene expression profiles.

3.5. Pirfenidone Improved the Histological Structure of the Lungs

Microscopic examination of the H&E-stained lung sections of both control (Figure 3a) and pirfenidone alone-treated (Figure 3b) groups revealed healthy histological structure of the rats' lungs. Healthy alveoli were lined by numerous thin squamous cells, type I pneumocytes, and a few thick cubical cells, type II pneumocytes. The alveoli were separated by thin interalveolar septa containing blood capillaries. Bronchioles were lined by columnar cells with thin underlying smooth muscle layers.

The allergic pneumonitis group (Figure 3c,d) displayed thick interalveolar septa due to massive cellular infiltrates mainly eosinophils, interalveolar edema, and dilated congested blood capillaries (Figure 3c). Bronchioles showed swollen walls due to thickened smooth muscle layer, eosinophil infiltration, and hypertrophied-folded epithelium intervened by goblet cells (Figure 3d). The CYP-exposed group (Figure 3e) showed distorted alveoli with disorganized epithelial lining. Dilated blood vessels and diffuse vascular congestion were also observed, with interalveolar and intra-alveolar extravasation of red blood cells.

However, an aggravated effect was noted in the allergic/CYP-exposed group (Figure 3f,g). The lung sections showed more bronchial affection with narrowing and partial obliteration of the alveoli. The bronchiolar walls were thicker than the allergic-only group due to hypertrophy of the bronchiolar epithelium with numerous intervening goblet cells, thickened smooth muscle layer, and massive peribronchiolar mononuclear cellular infiltrations (Figure 3f). The lung alveoli showed more thickening of the interalveolar septa with neutrophil infiltration leading to obliterated lumina (Figure 3g). The allergic/CYP/Dex-treated group (Figure 3h) showed persistent histopathological changes with resistance to dexamethasone treatment. The allergic/CYP/PFD-treated group (Figure 3i) showed remarkable improvement in the lung fields with the resolution of the edema and inflammation.

with the predominance of the M1 phenotype (CD86 + ve cells). (g,h) Allergic/CYP/PFD-treated group shows very few positive M1 (g) and M2 (h) phenotype macrophages. (o,p) representative figures of the mean number of the peribronchial (o) and parenchymal (p) CD86 and CD206 +ve macrophages at the end of the experiment, $n = 5$. Regarding CD86 immunopositivity, (a) significant versus control ($p < 0.001$). (b) significant versus allergic pneumonitis group ($p < 0.001$). (c) significant versus allergic/CYP-exposed group ($p < 0.001$). The capital letter refers to the comparison between groups regarding the CD206. The horizontal lines indicate the statistical significance and the p -value between M1 and M2 distribution within the same group using post hoc Tukey's two-way ANOVA. Scale bar: 50 μm (a–n).

3.8. Pirfenidone Reversed the Histomorphometric Measurements in the Lung Tissues

The mean eosinophil number was significantly greater ($p < 0.001$) in the allergic group when compared to the control and CYP alone group and significantly decreased ($p < 0.001$) in allergic/CYP-exposed groups. Dexamethasone had no further effect in comparison to allergic/CYP-exposed groups; however, PFD treatment had a significant ($p < 0.001$) effect (Figure 3j). In contrast, the mean neutrophil count was predominant ($p < 0.001$) after CYP exposure in the allergic rats (allergic/CYP-exposed), in comparison to the allergic pneumonitis-only group (Figure 3k), and their number was reversed ($p < 0.05$) by PFD but not dexamethasone treatment. Moreover, the allergic/CYP-exposed group showed a marked increase ($p < 0.05$) in the mean alveolar wall thickness (Figure 3l), mean goblet cell number (Figure 4h), and inflammation (Table 4) when compared to the allergic pneumonitis group. The mean area percentage of p38 MAPK immunoreactivity (Figure 5i) showed a marked ($p < 0.001$) p38 expression in the CYP-exposed allergic rats when compared to the allergic pneumonitis-only group. The p38 immunoreactivity was reversed ($p < 0.001$) by PFD versus Dex treatment. Regarding the dominant macrophage phenotype (Figure 6o,p), the lung CD206 immunoreactivity (an indicator of M2 phenotype) was significantly predominant ($p < 0.001$) in the allergic pneumonitis-only group. CYP exposure in allergically sensitized rats facilitated the macrophage shift ($p < 0.001$) toward the M1 phenotype, as indicated by the lung CD86 dominant expression, which was not reversed by dexamethasone. PFD-versus-dexamethasone treatment improved ($p < 0.05$) all the lung parameters and reduced ($p < 0.001$) both M1 and M2 macrophage phenotypes.

Table 4. The effect of PFD on the peribronchial and perivascular mononuclear cellular infiltration in the lung tissues of the studied groups at the end of the experiment.

	Peribronchiolar Inflammation	Perivascular Inflammation
Control	0.7 ± 0.67	0.4 ± 0.52
Pirfenidone (PFD)	0.9 ± 0.74	0.8 ± 0.79
Allergic	1.4 ± 0.84 ^a ($p = 0.03$)	1.2 ± 0.92 ^a ($p = 0.04$)
CYP	0.9 ± 0.73	0.6 ± 0.69
Allergic/CYP	3.1 ± 0.99 ^{ab} ($p < 0.001, = 0.001$)	2 ± 0.82 ^{ab} ($p = 0.001, = 0.03$)
Allergic/CYP/Dex	2.8 ± 0.92 ^{ab} ($p < 0.001, = 0.008$)	2.1 ± 0.88 ^{ab} ($p = 0.001, = 0.01$)
Allergic/CYP/PFD	1.4 ± 0.97 ^c ($p = 0.008$)	1.1 ± 0.99 ^c ($p = 0.03$)

All data are presented as mean ± SD, $n = 5$. ^a significant versus control, ^b significant versus allergic group, ^c significant versus allergic/CYP & allergic/CYP/Dex groups. Statistical significance and the p -value are shown between the groups using one-way ANOVA and post hoc Tukey's test.

4. Discussion

Utmost patients with classic asthma show a better response to conventional steroid therapy. Meanwhile, other patient classes exhibit steroid resistance and persistence of asthma, which entails a high dose and long-term glucocorticoid treatment [25]. The current findings showed that cypermethrin, a widely used pesticide with common indoor and outdoor exposures [26], aggravated lung inflammation and was associated with dexamethasone irresponsiveness in the OVA-immunized rats. Notably, PFD treatment improved

the histobiochemical pulmonary alterations and could replace dexamethasone treatment, bypassing steroid resistance. In accordance, Pelaia et al. [27] demonstrated that environmental triggers such as cigarette smoke, air pollutants, and lung infections could initiate severe Th2 low steroid-resistant asthma in susceptible individuals.

In the OVA-sensitized group, the histological and biochemical findings indicated classic eosinophilic asthma mediated by Th2 cell-dependent airway response (Th2-high inflammation). The results revealed upregulated IL13 gene/protein expression, eosinophilic pneumonitis, and upregulated *MUC5AC* gene expression coupled with goblet cell hyperplasia. Furthermore, *STAT6* gene expression was markedly upregulated, which was consistent with the findings mentioned earlier. In agreement, Chu et al. [28] mentioned a critical role for STAT6-associated pathways in the Th2 airway immune response and IL4/IL13 signaling. In the CYP-alone exposed group, the results displayed histological and biochemical features of a chemical-induced pneumonitis consistent with Pelaia et al. [27], who showed parallel pulmonary alterations.

Neutrophilic pneumonitis is a prominent feature of Th2 low-type mediated asthma and is commonly associated with severe asthma and steroid resistance [3]. In the current study, CYP-exposure of the allergic rats (allergic/CYP-exposed group) resulted in an aggravation of the allergic airway inflammation induced by OVA. Neutrophil recruitment, mononuclear cell infiltrates, and extensive goblet cells were prominent in the histological stains. In accordance, the BALF levels of Th1-related cytokine (INF- γ) and Th17-associated cytokine (IL17) were predominant. Marked lung oxidant/antioxidant imbalance was evident. Additionally, CYP further exaggerated *MUC5AC* gene upregulation, synergized *p38 MAPK* gene/protein expression, inhibited *STAT6* gene expression exerting STAT6-to-MAPK signaling shift and M2-to-M1 macrophage phenotype transition as demonstrated by the PCR findings and the immunohistochemical (IHC) observations. We speculated *p38 MAPK/STAT6* inverse relationship, where the activated *p38 MAPK* interacted with *STAT6* with inhibition of the latter. This assumption agreed with Athari [4], who declared *STAT6* activation blockage by interfering with the *STAT6-MAPK* interaction with *p38*.

Lung macrophages have intrinsic anti-inflammatory activity maintaining lung homeostasis via a balanced M1/M2 response. On lung injury, the resident macrophages can skew toward a proinflammatory phenotype based on their controlled switching ability between functional phenotypes [29]. In this study, the macrophage CD markers revealed the predominance of CD206 immunopositive M2 phenotype in the allergic pneumonitis-only group and switched to CD86 positive M1 phenotype after CYP exposure. Macrophage transformation is controlled by different transcription factors; the most important are STATs family. While *STAT6* directs M2 polarization, *STAT1* regulates M1 switch [5]. This notion emphasized our results of the *STAT6*-associated M2 polarization in the allergic pneumonitis-only group and the possible *p38*-related M1 polarization in the combined model group. The *p38*-induced *STAT6* inhibition might inhibit M2 phenotype during CYP exposure leading to M1 polarization shift and subsequent neutrophilic inflammation as suggested by Draijer et al [30].

Unlike the allergic pneumonitis-only group, which is classically influenced by the Th2 response, the airway neutrophilic inflammation observed in the allergic/CYP-exposed group might be attributed to further oxidative stress induced by CYP exposure that shifts the immune reactivity to INF- γ /Th-17 axis and *p38 MAPK* activation. Our suggestion was corroborated by Bao et al. [6], who reported a combined role of *p38 MAPK* and oxidative stress pathways in ozone-induced augmentation of lung inflammation in allergic mouse model. Therefore, we hypothesized an instantaneous inhibition of both oxidative stress and *p38 MAPK* pathways as a postulated mechanism of action for the pirfenidone ameliorative effects in the current combined model of CYP-exposure/OVA-sensitization. This theory was supported by Li et al. [31] and Fois et al. [32], who reported anti-oxidative and *p38* inhibitory activities for PFD as a basis for its antifibrotic effects.

Compared with the combined model group, *p38* gene/protein expression displayed a significant decrease with PFD treatment, meanwhile not with dexamethasone treatment.

Therefore, it was hypothesized that p38 signaling cascade might be involved in CYP-induced steroid-resistant asthma. The results revealed that CYP exposure increased p38 MAPK gene/protein expression in the structural cells of the lung, which was successfully suppressed by PFD. Despite the lack of PFD literary data on experimental models of allergic asthma, two previous studies [33,34] suggested a curative potential for PFD in the classic asthma phenotype by suppressing the BALF's inflammatory cytokine and platelet-derived growth factor, inhibiting TGF- β 1 expression, and reducing the goblet cell number & subepithelial fibrosis.

p38 upregulation, in the current study, was suggested as a reason for dexamethasone resistance. In agreement, Zeyen et al. [35] reported crosstalk between glucocorticoid receptors (GRs) and p38 MAPK, and the activation of the latter could impede GRs function and induce steroid resistance. Thus, the data propose PFD as a valid alternative to dexamethasone in steroid-resistant cases by modulating M1 macrophage polarization-associated p38 MAPK signaling pathway. Further studies are warranted to explore whether PFD might increase the pulmonary sensitivity to steroid treatment in steroid-resistant asthma.

The marked INF- γ upregulation in the combined model group might be an explanation for redirecting the inflammatory pathway, STAT6 downregulation, p38 MPAK activation, and hence, M2-to-M1 polarization shift. In their latest review, Abdelaziz et al. [36] supported our assumption. They reported that INF- γ (Th1-associated cytokine) could repress the Th2 cell lineage development, negatively affect STAT6 signaling, and activate M1 phenotype macrophage switch.

The current study was the first work to introduce the combined rat model of OVA-sensitization/CYP exposure. In addition, the study presented PFD as a potent alternative for dexamethasone in alleviating the augmented pulmonary immune response and the resistance to steroid treatment induced by CYP in allergic pneumonitis rats. However, the study had a few limitations. First, it did not introduce both PFD and Dex combined in one group to demonstrate whether PFD could fend off steroid resistance, and so, further information would be provided by future studies. Second, the quantification and characterization of the BALF's macrophages were limited in the current study. Additionally, the M2-to-M1 phenotype change needs further identification in association with studied markers. Third, the STAT6-to-p38 MAPK shift and signaling pathway need further investigations via studying protein phosphorylation using Western blot; otherwise, an *in vitro* experiment could be designed for investigating the PFD effect on STAT6/p38 MAPK pathway and its role in M1 macrophage differentiation.

In summary, CYP cannot initiate allergic asthma alone; it may provoke asthma as an environmental trigger with allergens through a mixed Th1/Th2-mediated airway inflammation. The findings showed that CYP exposure exaggerated the airway inflammation induced by ovalbumin sensitization and produced a full-blown picture of Th2 low severe asthma featured by steroid resistance, high INF- γ /IL17, neutrophilic pneumonitis, M1 phenotype predominance, and abundance of the epithelial goblet cells with mucous hypersecretion. The interaction between cytokines (IL13, INF- γ) and transcription factors (STAT6, p38 MAPK) played a critical role in this immune response. The present study presented CYP as an environmental trigger that could initiate severe dexamethasone-resistant asthma in sensitized rats. Furthermore, pirfenidone was suggested as a viable treatment option that protected against CYP-induced steroid-resistant allergic pneumonitis via M1 macrophage polarization suppression by modulating IL-13/STAT6 and INF- γ /p38 pathways.

Author Contributions: A.A.M. and E.M.F. conceptualized the research project, interpreted the photomicrographs, wrote the figure legend and text, and wrote the initial manuscript draft; B.B. and A.M.E.E. followed up the experiment, made the biochemical assays, and wrote the introduction, material, and method section; A.Y.A.H. and R.S.E.-s. organized and tabulated the research finding, prepared figure panels, and participated in the discussion; M.M.M. searched literature data and wrote the introduction; M.M.A. correlated the biochemical finding, wrote the initial draft, and funding the research; E.A.M. and A.M.A. interpreted the biochemical and molecular study results, correlated the findings, and shared in the discussion. All authors have read and agreed to the published version of the manuscript.

Funding: The Researchers Supporting Project number (RSPD2023R628), King Saud University, Riyadh, Saudi Arabia.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and was approved by the Research Ethics Committee at the Faculty of Medicine, Benha University, Egypt (approval #: RC11-10-2022).

Informed Consent Statement: Not applicable.

Data Availability Statement: All data generated or analyzed in the current study were included in the published article and any further explanations are available upon reasonable request.

Acknowledgments: The authors extend their appreciation to the Researchers Supporting Project, number (RSPD2023R628), King Saud University, Riyadh, Saudi Arabia.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Ali, R.; Ahmed, N.; Salman, M.; Daudpota, S.; Masroor, M.; Nasir, M. Assessment of Quality of Life in Bronchial Asthma Patients. *Cureus* **2020**, *12*, e10845. [[CrossRef](#)]
2. Rahbarghazi, R.; Keyhanmanesh, R.; Aslani, M.R.; Hassanpour, M.; Ahmadi, M. Bone Marrow Mesenchymal Stem Cells and Condition Media Diminish Inflammatory Adhesion Molecules of Pulmonary Endothelial Cells in an Ovalbumin-Induced Asthmatic Rat Model. *Microvasc. Res.* **2019**, *121*, 63–70. [[CrossRef](#)]
3. Zhang, X.; Xu, Z.; Wen, X.; Huang, G.; Nian, S.; Li, L.; Guo, X.; Ye, Y.; Yuan, Q. The Onset, Development and Pathogenesis of Severe Neutrophilic Asthma. *Immunol. Cell Biol.* **2022**, *100*, 144–159. [[CrossRef](#)] [[PubMed](#)]
4. Athari, S.S. Targeting Cell Signaling in Allergic Asthma. *Signal Transduct. Target. Ther.* **2019**, *4*, 45. [[CrossRef](#)]
5. Arora, S.; Dev, K.; Agarwal, B.; Das, P.; Syed, M.A. Macrophages: Their Role, Activation and Polarization in Pulmonary Diseases. *Immunobiology* **2018**, *223*, 383–396. [[CrossRef](#)] [[PubMed](#)]
6. Bao, A.; Yang, H.; Ji, J.; Chen, Y.; Bao, W.; Li, F.; Zhang, M.; Zhou, X.; Li, Q.; Ben, S. Involvements of P38 MAPK and Oxidative Stress in the Ozone-Induced Enhancement of AHR and Pulmonary Inflammation in an Allergic Asthma Model. *Respir. Res.* **2017**, *18*, 216. [[CrossRef](#)] [[PubMed](#)]
7. Nishida, C.; Yatera, K. The Impact of Ambient Environmental and Occupational Pollution on Respiratory Diseases. *Int. J. Environ. Res. Public Health* **2022**, *19*, 2788. [[CrossRef](#)]
8. Ghazouani, L.; Feriani, A.; Mufti, A.; Tir, M.; Baaziz, I.; Mansour, H.B.; Mnafigui, K. Toxic Effect of Alpha Cypermethrin, an Environmental Pollutant, on Myocardial Tissue in Male Wistar Rats. *Environ. Sci. Pollut. Res.* **2020**, *27*, 5709–5717. [[CrossRef](#)]
9. Wang, C.; Yang, Y.; Wu, N.; Gao, M.; Tan, Y. Combined Toxicity of Pyrethroid Insecticides and Heavy Metals: A Review. *Environ. Chem. Lett.* **2019**, *17*, 1693–1706. [[CrossRef](#)]
10. Cao, Z.; Liu, Y.; Zhang, Z.; Yang, P.; Li, Z.; Song, M.; Qi, X.; Han, Z.; Pang, J.; Li, B.; et al. Pirfenidone Ameliorates Silica-Induced Lung Inflammation and Fibrosis in Mice by Inhibiting the Secretion of Interleukin-17A. *Acta Pharmacol. Sin.* **2022**, *43*, 908–918. [[CrossRef](#)]
11. Bast, A.; Semen, K.O.; Drent, M. Pulmonary Toxicity Associated with Occupational and Environmental Exposure to Pesticides and Herbicides. *Curr. Opin. Pulm. Med.* **2021**, *27*, 278–283. [[CrossRef](#)] [[PubMed](#)]
12. Jasemi, S.V.; Khazaei, H.; Fakhri, S.; Mohammadi-Noori, E.; Farzaei, M.H. Naringenin Improves Ovalbumin-Induced Allergic Asthma in Rats through Antioxidant and Anti-Inflammatory Effects. *Evid. Based Complement. Altern. Med.* **2022**, *2022*, 9110798. [[CrossRef](#)] [[PubMed](#)]
13. Tang, H.; Han, X.; Li, T.; Feng, Y.; Sun, J. Protective Effect of MiR-138-5p Inhibition Modified Human Mesenchymal Stem Cell on Ovalbumin-induced Allergic Rhinitis and Asthma Syndrome. *J. Cell. Mol. Med.* **2021**, *25*, 5038–5049. [[CrossRef](#)] [[PubMed](#)]
14. Afolabi, O.K.; Aderibigbe, F.A.; Folarin, D.T.; Arinola, A.; Wusu, A.D. Oxidative Stress and Inflammation Following Sub-Lethal Oral Exposure of Cypermethrin in Rats: Mitigating Potential of Epicatechin. *Heliyon* **2019**, *5*, e02274. [[CrossRef](#)] [[PubMed](#)]
15. Ezz-Eldin, Y.M.; Aboseif, A.A.; Khalaf, M.M. Potential Anti-Inflammatory and Immunomodulatory Effects of Carvacrol against Ovalbumin-Induced Asthma in Rats. *Life Sci.* **2020**, *242*, 117222. [[CrossRef](#)]

16. Livak, K.J.; Schmittgen, T.D. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the $2^{-\Delta\Delta C_T}$ Method. *Methods* **2001**, *25*, 402–408. [[CrossRef](#)]
17. Tataurov, A.V.; You, Y.; Owczarzy, R. Predicting Ultraviolet Spectrum of Single Stranded and Double Stranded Deoxyribonucleic Acids. *Biophys. Chem.* **2008**, *133*, 66–70. [[CrossRef](#)]
18. Bancroft, J.D.; Layton, C. Connective and Other Mesenchymal Tissues and Their Stains. In *Bancroft's Theory and Practice of Histological Techniques E-Book*; Elsevier Health Sciences: Amsterdam, The Netherlands, 2018; pp. 153–175.
19. Kiernan, J.A. Immunohistochemistry. In *Histological and Histochemical Methods. Theory and Practice*; Kiernan, J., Ed.; Scion Publishing Ltd.: Banbury, UK, 2015; pp. 454–490.
20. Rasband, W.S. *ImageJ (1997–2007)*; US National Institutes of Health: Bethesda, MD, USA, 2007. Available online: <https://imagej.nih.gov/ij/> (accessed on 1 January 2023).
21. Tang, X.; Nian, H.; Li, X.; Yang, Y.; Wang, X.; Xu, L.; Shi, H.; Yang, X.; Liu, R. Effects of the Combined Extracts of Herba Epimedii and Fructus Ligustrilucidi on Airway Remodeling in the Asthmatic Rats with the Treatment of Budesonide. *BMC Complement. Altern. Med.* **2017**, *17*, 112. [[CrossRef](#)]
22. Mesnil, C.; Raulier, S.; Paulissen, G.; Xiao, X.; Birrell, M.A.; Pirotton, D.; Janss, T.; Starkl, P.; Ramery, E.; Henket, M.; et al. Lung-Resident Eosinophils Represent a Distinct Regulatory Eosinophil Subset. *J. Clin. Investig.* **2016**, *126*, 3279–3295. [[CrossRef](#)]
23. Wu, Z.; Mehrabi Nasab, E.; Arora, P.; Athari, S.S. Study Effect of Probiotics and Prebiotics on Treatment of OVA-LPS-Induced of Allergic Asthma Inflammation and Pneumonia by Regulating the TLR4/NF-KB Signaling Pathway. *J. Transl. Med.* **2022**, *20*, 130. [[CrossRef](#)]
24. Faul, F.; Erdfelder, E.; Buchner, A.; Lang, A.-G. Statistical Power Analyses Using G* Power 3.1: Tests for Correlation and Regression Analyses. *Behav. Res. Methods* **2009**, *41*, 1149–1160. [[CrossRef](#)]
25. Liang, L.; Gu, X.; Shen, H.J.; Shi, Y.H.; Li, Y.; Zhang, J.; Chen, Y.Y.; Chen, Z.H.; Ma, J.Y.; Li, Q.Y. Chronic Intermittent Hypoxia Reduces the Effects of Glucocorticoid in Asthma via Activating the P38 MAPK Signaling Pathway. *Front. Physiol.* **2021**, *12*, 703281. [[CrossRef](#)] [[PubMed](#)]
26. Soliman, N.I.; El-Desouky, M.; Nahas, A.E.-H.A.E.-M. Cypermethrin-Induced Lung Damage in Albino Rats: The Preventive Impact of Moringa Oleifera. *Egypt. J. Chem.* **2021**, *64*, 5585–5595. [[CrossRef](#)]
27. Pelaia, C.; Vatrella, A.; Gallelli, L.; Lombardo, N.; Sciacqua, A.; Savino, R.; Pelaia, G. Role of P38 Mitogen-Activated Protein Kinase in Asthma and COPD: Pathogenic Aspects and Potential Targeted Therapies. *Drug Des. Dev. Ther.* **2021**, *15*, 1275–1284. [[CrossRef](#)] [[PubMed](#)]
28. Chu, K.-H.; Lin, S.-Y.; Chiang, B.-L. STAT6 Pathway Is Critical for the Induction and Function of Regulatory T Cells Induced by Mucosal B Cells. *Front. Immunol.* **2021**, *11*, 615868. [[CrossRef](#)]
29. Lee, Y.G.; Jeong, J.J.; Nyenhuis, S.; Berdyshev, E.; Chung, S.; Ranjan, R.; Karpurapu, M.; Deng, J.; Qian, F.; Kelly, E.A.B. Recruited Alveolar Macrophages, in Response to Airway Epithelial-Derived Monocyte Chemoattractant Protein 1/CCL2, Regulate Airway Inflammation and Remodeling in Allergic Asthma. *Am. J. Respir. Cell Mol. Biol.* **2015**, *52*, 772–784. [[CrossRef](#)]
30. Draijer, C.; Robbe, P.; Boorsma, C.E.; Hylkema, M.N.; Melgert, B.N. Dual Role of YM1+ M2 Macrophages in Allergic Lung Inflammation. *Sci. Rep.* **2018**, *8*, 5105. [[CrossRef](#)]
31. Li, Z.; Liu, X.; Wang, B.; Nie, Y.; Wen, J.; Wang, Q.; Gu, C. Pirfenidone Suppresses MAPK Signalling Pathway to Reverse Epithelial-mesenchymal Transition and Renal Fibrosis. *Nephrology* **2017**, *22*, 589–597. [[CrossRef](#)]
32. Fois, A.G.; Posadino, A.M.; Giordo, R.; Cossu, A.; Agouni, A.; Rizk, N.M.; Pirina, P.; Carru, C.; Zinellu, A.; Pintus, G. Antioxidant Activity Mediates Pirfenidone Antifibrotic Effects in Human Pulmonary Vascular Smooth Muscle Cells Exposed to Sera of Idiopathic Pulmonary Fibrosis Patients. *Oxid. Med. Cell. Longev.* **2018**, *2018*, 2639081. [[CrossRef](#)]
33. Hirano, A.; Kanehiro, A.; Ono, K.; Ito, W.; Yoshida, A.; Okada, C.; Nakashima, H.; Tanimoto, Y.; Kataoka, M.; Gelfand, E.W.; et al. Pirfenidone Modulates Airway Responsiveness, Inflammation, and Remodeling after Repeated Challenge. *Am. J. Respir. Cell Mol. Biol.* **2006**, *35*, 366–377. [[CrossRef](#)]
34. Mansoor, J.K.; Decile, K.C.; Giri, S.N.; Pinkerton, K.E.; Walby, W.F.; Bratt, J.M.; Grewal, H.; Margolin, S.B.; Schelegle, E.S. Influence of Pirfenidone on Airway Hyperresponsiveness and Inflammation in a Brown-Norway Rat Model of Asthma. *Pulm. Pharmacol. Ther.* **2007**, *20*, 660–668. [[CrossRef](#)] [[PubMed](#)]
35. Zeyen, L.; Seternes, O.M.; Mikkola, I. Crosstalk between P38 MAPK and GR Signaling. *Int. J. Mol. Sci.* **2022**, *23*, 3322. [[CrossRef](#)] [[PubMed](#)]
36. Abdelaziz, M.H.; Abdelwahab, S.F.; Wan, J.; Cai, W.; Huixuan, W.; Jianjun, C.; Kumar, K.D.; Vasudevan, A.; Sadek, A.; Su, Z.; et al. Alternatively Activated Macrophages; a Double-Edged Sword in Allergic Asthma. *J. Transl. Med.* **2020**, *18*, 58. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.